{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:47:04Z","timestamp":1791424024368,"version":"4.3.3"},"reference-count":76,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T00:00:00Z","timestamp":1370822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH","award":["2P30AI050409"],"award-info":[{"award-number":["2P30AI050409"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Interferon\u2010based standard of care treatments (<jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>) for chronic hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> are unable to provide high cure rates in certain subgroups of the infected population and can cause debilitating side effects. Clinical trials evaluating all\u2010oral, interferon\u2010free treatments have demonstrated high rates of sustained virologic response with no resistance or major adverse events in most populations. As these drug regimens move towards <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> approval, it will be important to assess their cost\u2010effectiveness in addition to their clinical efficacy. A decision\u2010analytic <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>arkov model with a lifetime, societal perspective was used to evaluate the cost\u2010effectiveness of a generalized all\u2010oral drug regimen compared to <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content> by modelling the progression of a 50\u2010year\u2010old, <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010positive cohort through disease natural history and treatment. In base case analysis, all\u2010oral treatment dominated <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content> across a range of willingness\u2010to\u2010pay (<jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content>) thresholds with an incremental cost\u2010effectiveness ratio (<jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content>) of <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>$44\u00a0514\/quality\u2010adjusted life year (<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>). In sensitivity analyses, the model was sensitive to all\u2010oral drug costs as well as rates of <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> and treatment uptake among noncirrhotic subjects, but robust to variations in all other parameters. All\u2010oral treatment was most cost\u2010effective among genotype 1 subjects but remained cost\u2010effective for genotypes 2 and 3 at <jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content> thresholds \u2265$80\u00a0000\/<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>. Quality\u2010adjusted life years gained per dollar spent were maximized in younger treatment cohorts. Using this model, the degree of cost\u2010effectiveness depended on the <jats:styled-content style=\"fixed-case\">WTP<\/jats:styled-content> threshold and the final cost set for approved drug combinations.<\/jats:p>","DOI":"10.1111\/jvh.12111","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T07:28:51Z","timestamp":1370849331000},"page":"847-857","source":"Crossref","is-referenced-by-count":49,"title":["All\u2010oral, interferon\u2010free treatment for chronic hepatitis <scp>C<\/scp>: cost\u2010effectiveness analyses"],"prefix":"10.1111","volume":"20","author":[{"given":"L. M.","family":"Hagan","sequence":"first","affiliation":[{"name":"Department of Pediatrics Laboratory of Biochemical Pharmacology Center for AIDS Research Emory University School of Medicine Atlanta GA USA"},{"name":"Emory University Rollins School of Public Health Atlanta GA USA"},{"name":"Veterans Affairs Medical Center Decatur GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Yang","sequence":"additional","affiliation":[{"name":"Emory University Rollins School of Public Health Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ehteshami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Laboratory of Biochemical Pharmacology Center for AIDS Research Emory University School of Medicine Atlanta GA USA"},{"name":"Veterans Affairs Medical Center Decatur GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Laboratory of Biochemical Pharmacology Center for AIDS Research Emory University School of Medicine Atlanta GA USA"},{"name":"Veterans Affairs Medical Center Decatur GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,10]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"World Health Organization [Internet].Hepatitis C Fact Sheet[cited 2012 Jul 1]. Available at:http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html. (accessed 1 July 2012)."},{"key":"e_1_2_8_3_1","volume-title":"Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis","author":"United States Department of Health and Human Services","year":"2011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00004"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.05.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.90.10.1562"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00378"},{"key":"e_1_2_8_8_1","unstructured":"Centers for Disease Control and Prevention [Internet].CDC Announces First ever National Hepatitis Testing Day and Proposes that all Baby Boomers be Tested once for Hepatitis C[cited 2012 July 22]. Available at:http:\/\/www.cdc.gov\/nchhstp\/newsroom\/HepTestingRecsPressRelease2012.html. (accessed 22 July 2012)."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00014"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct061675"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"issue":"3","key":"e_1_2_8_14_1","first-page":"1","article-title":"NIH consensus statement on management of hepatitis C","volume":"19","author":"National Institutes of Health","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_8_15_1","unstructured":"Inciveck\/telaprevir (package insert).Cambridge MA:Vertex Pharmaceuticals. October 2012."},{"key":"e_1_2_8_16_1","unstructured":"Victrelis\/boceprevir (package insert).Whitehouse Station NJ:Merck & Co Inc. May 2011."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01246.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12063"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir306"},{"key":"e_1_2_8_21_1","volume-title":"Compressed Mortality File 1999\u20132007 Series 20 No. 2M, 2010","author":"National Center for Health Statistics [Internet]","year":"2010"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.038257"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50073"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200708"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00001"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.31"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis011"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00005"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03037.x"},{"key":"e_1_2_8_34_1","volume-title":"The State of Care for Veterans with Chronic Hepatitis C","author":"Center for Quality Management in Public Health","year":"2010"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.57"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.08.012"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir076"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.044"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-6-200809160-00006"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22694"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.157"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33023"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.10.036"},{"key":"e_1_2_8_44_1","volume-title":"UBS Q\u2010series: is the HCV market investable long term? A new analysis of diagnosis and treatment rates","author":"UBS Securities","year":"2012"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.2.228"},{"key":"e_1_2_8_46_1","unstructured":"KowdleyK LawitzE PoordadF CohenD NelsonD ZeuzemS et al.A 12\u2010week interferon\u2010free treatment regimen with ABT\u2010450\/r ABT\u2010267 ABT\u2010333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment\u2010naive patients and 93% in prior null responders with HCV genotype 1 infection. Proceedings of The Liver Meeting 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9\u201013; Boston Massachusetts USA."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"e_1_2_8_48_1","unstructured":"CardosoA MoucariR GiuilyN Figueiredo\u2010MendesC BoyerN RipaultM et al.Sustained virological response is associated with reversibility of cirrhosis in chronic hepatitis C patients. Proceedings of the International Liver Congress 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18\u201022; Barcelona Spain."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41860.x"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099150"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00951-2"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.374"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31802dc56f"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01137.x"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10320"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.04.009"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.009"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"e_1_2_8_61_1","doi-asserted-by":"crossref","unstructured":"SulkowskiM GardinerD LawitzE HinestrosaF NelsonD ThuluvathP et al.Potent viral suppression with the all\u2010oral combination of daclatasvir (NS5A inhibitor) and GS\u20107977 (nucleoside NS5B inhibitor) +\/\u2010 ribavirin in treatment\u2010naive patients with chronic HCV GT1 2 or 3 (100% SVR GT1 91% GT2). Proceedings of the International Liver Congress 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18\u201022; Barcelona Spain.","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"e_1_2_8_62_1","unstructured":"ZeuzemS SorianoV AsselahT BronowickiJ LohseA M\u00fcllhauptB et al.SOUND\u2010C2 interim results: high efficacy good safety profile of IFN\u2010free BI 201335 BI 207127 and RBV combination therapy in treatment\u2010naive patients with genotype 1 HCV. Proceedings of the International Liver Congress 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18\u201022; Barcelona Spain."},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7106.453"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00698.x"},{"key":"e_1_2_8_65_1","unstructured":"PawlotskyJ SarinS FosterG PengC RasenackJ FlisiakR et al.Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)\u2010free or IFN\u2010add\u2010on regimen in treatment\u2010naive patients with HCV GT2 or GT3: final results from VITAL\u20101 study. Proceedings of The Liver Meeting 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9\u201013; Boston Massachusetts USA."},{"key":"e_1_2_8_66_1","unstructured":"SulkowskiM GardinerD Rodriguez\u2010TorresM ReddyR HassaneinT JacobsonI et al.High rate of sustained virologic response with the all\u2010oral combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor) with or without ribavirin in treatment\u2010naive patients chronically infected with HCV genotype 1 2 or 3. Proceedings of The Liver Meeting 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9\u201013; Boston Massachusetts USA."},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40976.x"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.31345"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604301"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02152.x"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315240"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22072"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300518"},{"key":"e_1_2_8_74_1","volume-title":"Cost of digestive diseases in the United States","author":"Brown DM","year":"1994"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22129"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.15.1381"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2088"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T11:19:04Z","timestamp":1696159144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,10]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/jvh.12111"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12111","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,10]]}}}